Bruce Korf, MD
Enriched profileDistinguished Professor of Genetics; Associate Dean for Genomic Medicine and Chief Genomics Officer · University of Alabama at Birmingham
Bruce Korf is Distinguished Professor of Genetics; Associate Dean for Genomic Medicine and Chief Genomics Officer at University of Alabama at Birmingham. OpenAlex indexes 534 publications with 27,313 citations (h-index 77); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 11 Oct 2026
Overview
Updated 16 Oct 2026
Bruce Korf is Distinguished Professor of Genetics at University of Alabama at Birmingham, Heersink School of Medicine. The public record shows 534 publications with 27,313 citations (h-index 77), centered on Neurofibromatosis and Schwannoma Cases, Genomics and Rare Diseases, Neuroblastoma Research and Treatments. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 2 companies, 10 NIH-funded awards (2003–2026).
- Most recent indexed publication: 2026 · Journal of community genetics
- Top research focus: Neurofibromatosis and Schwannoma Cases
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 229.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
Sponsor: University of Alabama at Birmingham
- Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
Sponsor: National Cancer Institute (NCI)
- A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)
Sponsor: University of Alabama at Birmingham
Industry payments
Updated 16 Oct 2026
2 companies reported payments to CMS in program years 2022–2024. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year202410 payments
- SpringWorks Therapeutics, Inc.Program year20241 payment
- Alexion Pharmaceuticals, Inc.Program year202313 payments$13,466openpaymentsdata.cms.gov ↗
NIH funding
Updated 16 Oct 2026
10 NIH research awards on record, funded 2003–2026 per NIH RePORTER. The latest:
- Increasing Access, Diagnostic Yield, and Efficiency in Clinical Evaluations of Rare Disorders
University of Alabama at Birmingham
FY2026$727,518U01NS139216
Congress activity
Updated 16 Oct 2026
3 congress contributions (2010–2019) across AACR, ASCO per OpenAlex. The most recent:
- Phase II study of the mTOR inhibitor sirolimus for nonprogressive NF1-associated plexiform neurofibromas: A Neurofibromatosis Consortium study.
ASCO Annual Meeting
ASCO2010Co-authorOnline-only
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Integrating genomic medicine into primary care -examining perceptions of community advisory board members.
Journal of community genetics
Article2026 - Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.
Pediatric blood & cancer
Clinical Trial2021 - NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Journal of clinical oncology
Clinical Trial2021
Most-cited works
by citation count (OpenAlex)- 01ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencingArticle2,546 citations2013
- 02
- 03
- 04Neurofibromatosis type 1Review862 citations2017
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/bruce-korf-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
PhD
- Board certified
American Board of Medical Genetics (clinical genetics, clinical cytogenetics, clinical molecular genetics)
- Board certified
American Board of Pediatrics
- Board certified
American Board of Psychiatry and Neurology (child neurology)
Editorial & leadership roles
journal and society appointments- Past President
American College of Medical Genetics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗ - Past President
ACMG Foundation for Genetic and Genomic Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗ - Editor-in-Chief
American Journal of Human Genetics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →prnewswire.com ↗
Awards & honors
honors on the public record- David L. Rimoin Lifetime Achievement Award in Medical Genetics
ACMG Foundation for Genetic and Genomic Medicine
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uab.edu ↗
Secondary affiliations
appointments beyond the home institution- Co-Director
UAB-HudsonAlpha Center for Genomic Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →providerdirectory.uabmedicine.org ↗
Media & interviews
press, podcasts and appearances- Bruce Korf
MD, PhD Discusses Genomic Medicine, Birmingham Medical News
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →birminghammedicalnews.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Whitley, MD
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Michael Mugavero, MD
University of Alabama at Birmingham
Boni Elewski, MD
University of Alabama at Birmingham